Cidara has received a grant for up to $6.9 million from CARB-X (Combating Antibiotic Resistant Bacteria Accelerator) to advance the development of its antibiotic immunotherapy, CD201, for the treatment of life-threatening multi-drug resistant bacteria. CARB-X is the world’s largest public-private partnership focused on antibacterials.
Powered by
Recent News and Insights
-
Cidara to Participate in the 2017 BIO International Convention June 15 2017
-
Cidara Announces Presentations at ASM Microbe 2017 and the 22nd Congress of the European Hematology Association May 30, 2017
-
Cidara Provides Corporate Update and Reports First Quarter 2017 Financial Results May 10, 2017
-
View all News Releases
Our Mission
Cidara seeks to save or improve patients’ lives through the development of anti-infectives that transform the standard of care. Our initial portfolio is comprised of proprietary product candidates for the treatment of serious fungal and bacterial infections.
There is an urgent and growing need not only for improved anti-infectives but also for entirely new therapeutic approaches to treat and prevent fungal, bacterial, and viral pathogens, particularly those that are increasingly resistant to available treatments.
CD101 IV
CD101 IV is a novel echinocandin antifungal with potent activity against Candida, Aspergillus and PCP. We are developing CD101 IV for once weekly use. We have completed Phase 1 trials and are currently conducting an international Phase 2 trial (STRIVE) in candidemia.
Cloudbreak™ / CD201
Cloudbreak is a proprietary immunotherapy discovery platform that has the potential to do for infectious disease what immunotherapy has done for cancer. CD201 is our lead Cloudbreak candidate intended to direct a patient’s immune cells to attack bacterial infections.